MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that on March 26, 2025, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders’ equity was less than $50 million..

马尔文，宾夕法尼亚州，2025年3月27日（GLOBE NEWSWIRE）——Annovis Bio公司（纽约证券交易所代码：ANVS）（“Annovis”或“公司”），一家致力于为阿尔茨海默病（AD）和帕金森病（PD）等神经退行性疾病开发革命性疗法的晚期临床药物平台公司，今日宣布于2025年3月26日收到纽约证券交易所（NYSE）发出的通知（“通知”），称公司不再符合NYSE《上市公司手册》第802.01B节中规定的持续上市标准，原因是公司在连续30个交易日内的平均全球市值低于5000万美元，同时其股东权益也低于5000万美元。

The Notice does not affect the Company’s business operations or its reporting obligations with the Securities and Exchange Commission, and it does not conflict with or cause an event of default under any of the Company’s material debt or other agreements.

该通知不会影响公司的业务运营或其向证券交易委员会的报告义务，且不会与公司任何重大债务或其他协议发生冲突或导致违约事件。

As set forth in the Notice, as of March 25, 2025, the 30 trading-day average market capitalization of the Company was approximately $37.9 million and the Company’s last reported stockholders’ equity as of December 31, 2024 was $9.3 million.

根据公告所述，截至 2025 年 3 月 25 日，公司 30 个交易日的平均市值约为 3790 万美元，截至 2024 年 12 月 31 日，公司最近报告的股东权益为 930 万美元。

The Company has notified the NYSE that it will submit a plan within 45 days of the Notice advising the NYSE of definitive action it has taken, or is taking, to bring it into conformity with Section 802.01B within 18 months of receipt of the Notice. The NYSE will review the Company’s plan and, within 45 days, make a determination as to whether the Company has made a reasonable demonstration of its ability to come into conformity with Section 802.01B within 18 months.

公司已通知纽约证券交易所，将在收到通知后的45天内提交一份计划，告知其已采取或正在采取的明确行动，以在收到通知后的18个月内符合第802.01B条的规定。纽约证券交易所将审查公司的计划，并在45天内决定公司是否合理证明了其能够在18个月内符合第802.01B条的规定。

If the Company’s plan is not submitted on a timely basis or is not accepted, the NYSE will initiate delisting proceedings. If the NYSE accepts the Company’s plan, the Company’s common stock will continue to be listed and traded on the NYSE during the cure period, subject to the Company’s compliance with the plan and other continued listing standards.

如果公司未能按时提交计划或计划未获接受，纽交所将启动退市程序。如果纽交所接受公司的计划，公司的普通股将在整改期内继续在纽交所上市和交易，但需遵守该计划及其他持续上市标准。

The NYSE will review the Company on a quarterly basis to confirm compliance with the plan. If the Company fails to comply with the plan or does not meet continued listing standards at the end of the 18-month cure period, it will be subject to the prompt initiation of NYSE suspension and delisting procedures..

纽约证券交易所将每季度审查一次公司，以确认其是否遵守该计划。如果公司在18个月的补救期结束时未能遵守该计划或未达到持续上市标准，将面临纽约证券交易所迅速启动的停牌和退市程序。

The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be “ANVS”, subject to the Company’s continued compliance with the plan and other listing requirements of the NYSE. However, the common stock trading symbol will have an added designation of “.BC” to indicate that the status of the common stock is below criteria with the NYSE continued listing standards.

该通知不会立即影响公司普通股的上市，其股票代码仍将是“ANVS”，但前提是公司继续遵守纽约证券交易所的计划和其他上市要求。然而，普通股的交易代码将增加“.BC”的标识，以表明该股票的状态未达到纽约证券交易所的持续上市标准。

The “.BC” indicator will be removed at such time as the Company regains compliance..

“.BC”标识将在公司重新合规时移除。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的注意事项

This press release contains, and oral statements made from time to time by our representatives may contain, “forward-looking statements.” Forward-looking statements include statements identified by words such as “could,” “may,” “might,” “will,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods, or by the inclusion of forecasts or projections.

本新闻稿包含且我们的代表不时作出的口头声明可能包含“前瞻性陈述”。前瞻性陈述包括通过诸如“可能”、“也许”、“将会”、“打算”、“计划”、“寻求”、“相信”、“估计”、“预期”、“继续”、“展望”等词语识别的陈述，或通过包含预测或预测值而指代未来时期的类似表述。

Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict.

前瞻性声明基于我们对资本市场状况、我们的业务、经济及其他未来状况的当前预期和假设。由于前瞻性声明与未来相关，因此其性质上存在固有的不确定性、风险以及难以预测的情况变化。

As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the Company’s ability to develop a plan to regain compliance with the continued listing criteria of the NYSE; the NYSE’s acceptance of such plan; the Company’s ability to execute such plan and to continue to comply with applicable listing standards within the available cure period; risks arising from the potential suspension of trading of the Company’s common stock on the NYSE; regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks regarding our ability to manage inventory or anticipate consumer demand; changes in consumer confidence and spending; our competitive environment; our failure to open new profitable stores or successfully enter new markets and other factors set forth u.

因此，我们的实际结果可能与前瞻性声明中所设想的结果存在重大差异。导致实际结果与前瞻性声明中的结果存在重大差异的重要因素包括但不限于：公司制定恢复遵守纽约证券交易所持续上市标准计划的能力；纽约证券交易所对该计划的接受程度；公司执行该计划并在可用补救期内继续遵守适用上市标准的能力；公司普通股在纽约证券交易所可能被暂停交易的风险；地区、国家或全球的政治、经济、商业、竞争、市场和监管状况，包括关于我们管理库存或预测消费者需求能力的风险；消费者信心和支出的变化；我们的竞争环境；我们未能开设新的盈利店铺或成功进入新市场以及其他列出的因素。

About Annovis Bio, Inc.:

关于Annovis Bio公司：

Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X..

总部位于宾夕法尼亚州马尔文的 Annovis 致力于解决阿尔茨海默病 (AD) 和帕金森病 (PD) 等疾病中的神经退行性病变。公司创新的方法针对多种神经毒性蛋白，旨在恢复大脑功能并改善患者的生活质量。欲了解更多信息，请访问 www.annovisbio.com，并在 LinkedIn、YouTube 和 X 上关注我们。

Contact:

联系人：

Annovis Bio Inc.

安诺维斯生物公司

101 Lindenwood Drive

林登伍德大道101号

Suite 225

225号套房

Malvern, PA 19355

宾夕法尼亚州马尔文，邮编19355

www.annovisbio.com

www.annovisbio.com

Investor Contact:

投资者联系方式：

Alexander Morin, Ph.D.

亚历山大·莫林，博士

Director, Strategic Communications

战略传播总监

Annovis Bio

安诺维斯生物

ir@annovisbio.com

投资者关系@annovis生物公司.com